Design and Fabrication of Environmentally Responsive Nanoparticles for the Diagnosis and Treatment of Atherosclerosis
Source abstract
Abstract
Cardiovascular disease poses a significant threat to human health in today's society. A major contributor to cardiovascular disease is atherosclerosis (AS). The development of plaque in the affected areas involves a complex pathological environment, and the disease progresses rapidly. Nanotechnology, combined with emerging diagnostic and treatment methods, offers the potential for the management of this condition. This paper presents the latest advancements in environment-intelligent responsive controlled-release nanoparticles designed specifically for the pathological environment of AS, which includes characteristics such as low pH, high reactive oxygen species levels, high shear stress, and multienzymes. Additionally, the paper summarizes the applications and features of nanotechnology in interventional therapy for AS, including percutaneous transluminal coronary angioplasty and drug-eluting stents. Furthermore, the application of nanotechnology in the diagnosis of AS shows promising real-time, accurate, and continuous effects. Lastly, the paper explores the future prospects of nanotechnology, highlighting the tremendous potential in the diagnosis and treatment of atherosclerotic diseases, especially with the ongoing development in nano gas, quantum dots, and Metal-Organic Frameworks materials.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Nanoparticles: synthesis and applications
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Key Lab. for Advanced Technologies of Materials, Ministry of Education, School of Material Science and Engineering, Southwest Jiaotong University, Chengdu 610031, PR China
Funding
Southwest Jiaotong University · Sichuan Province Science and Technology Support Program
References (100+)
Show source-provided references
1. 10.1001/jama.2020.1873110.1001/jama.2020.18731 ↗
2. World Health Statistics 2021 https://apps.who.int/iris/bitstream/handle/10665/342703/9789240027053-eng.pdf. DB/OL 2021.
3. 10.1161/CIRCRESAHA.118.31381610.1161/CIRCRESAHA.118.313816 ↗
4. 10.1038/s41572-019-0116-x10.1038/s41572-019-0116-x ↗
5. 10.21037/cdt.2020.02.0910.21037/cdt.2020.02.09 ↗
6. 10.1016/j.jacc.2018.12.07510.1016/j.jacc.2018.12.075 ↗
7. 10.1002/smll.20170279310.1002/smll.201702793 ↗
8. 10.1016/j.tcm.2019.01.00110.1016/j.tcm.2019.01.001 ↗
9. 10.1016/j.jacc.2009.07.02610.1016/j.jacc.2009.07.026 ↗
10. 10.1016/j.atherosclerosis.2003.07.00310.1016/j.atherosclerosis.2003.07.003 ↗
11. 10.1016/j.atherosclerosis.2022.02.01010.1016/j.atherosclerosis.2022.02.010 ↗
12. 10.1016/0753-3322(90)90133-T10.1016/0753-3322(90)90133-T ↗
13. 10.1016/0167-5273(85)90194-910.1016/0167-5273(85)90194-9 ↗
14. Block P. C. · Circulation · 1985 · 2933184
15. 10.1016/j.jvir.2010.02.03210.1016/j.jvir.2010.02.032 ↗
16. 10.1227/01.NEU.0000255521.42579.3110.1227/01.NEU.0000255521.42579.31 ↗
17. 10.1093/rb/rbw01810.1093/rb/rbw018 ↗
18. 10.1016/j.avsg.2021.04.01510.1016/j.avsg.2021.04.015 ↗
19. 10.1016/j.jcin.2018.11.04010.1016/j.jcin.2018.11.040 ↗
20. 10.1161/CIRCRESAHA.117.31027510.1161/CIRCRESAHA.117.310275 ↗
21. 10.1016/j.wneu.2017.01.12710.1016/j.wneu.2017.01.127 ↗
22. 10.1016/j.addr.2023.11470910.1016/j.addr.2023.114709 ↗
23. 10.1093/oxfordjournals.eurheartj.a01541910.1093/oxfordjournals.eurheartj.a015419 ↗
24. 10.1111/j.1749-6632.1992.tb17102.x10.1111/j.1749-6632.1992.tb17102.x ↗
25. 10.1007/s10557-016-6649-210.1007/s10557-016-6649-2 ↗
26. 10.1021/acsbiomaterials.0c0028110.1021/acsbiomaterials.0c00281 ↗
27. 10.1155/2021/666447110.1155/2021/6664471 ↗
28. 10.1016/j.apsb.2022.11.01410.1016/j.apsb.2022.11.014 ↗
29. 10.1186/s12951-023-02058-z10.1186/s12951-023-02058-z ↗
30. 10.3390/ma1105075410.3390/ma11050754 ↗
31. 10.3390/pharmaceutics1211105610.3390/pharmaceutics12111056 ↗
32. 10.1080/17435390.2020.184253710.1080/17435390.2020.1842537 ↗
33. 10.1042/BJ2015084410.1042/BJ20150844 ↗
34. 10.1016/j.cej.2023.14679210.1016/j.cej.2023.146792 ↗
35. 10.1021/acsami.2c0235410.1021/acsami.2c02354 ↗
36. 10.1016/j.biomaterials.2022.12173410.1016/j.biomaterials.2022.121734 ↗
37. 10.7150/thno.7089610.7150/thno.70896 ↗
38. 10.1016/j.bioactmat.2022.03.04110.1016/j.bioactmat.2022.03.041 ↗
39. 10.1016/j.jconrel.2017.03.39210.1016/j.jconrel.2017.03.392 ↗
40. 10.1039/D1TB00330E10.1039/D1TB00330E ↗
41. 10.1002/adma.20130568310.1002/adma.201305683 ↗
42. 10.1021/acsnano.3c0352310.1021/acsnano.3c03523 ↗
43. 10.1002/smll.20220096710.1002/smll.202200967 ↗
44. 10.1016/j.cej.2019.12346510.1016/j.cej.2019.123465 ↗
45. 10.1007/s11051-017-4045-x10.1007/s11051-017-4045-x ↗
46. 10.1016/j.jmmm.2018.11.13210.1016/j.jmmm.2018.11.132 ↗
47. 10.1007/s10439-020-02589-810.1007/s10439-020-02589-8 ↗
48. 10.1021/acsami.6b0390510.1021/acsami.6b03905 ↗
49. 10.2147/IJN.S37187310.2147/IJN.S371873 ↗
50. 10.1016/j.actbio.2020.03.04110.1016/j.actbio.2020.03.041 ↗
51. 10.1093/rb/rbaa01910.1093/rb/rbaa019 ↗
52. 10.1016/j.addr.2022.11439410.1016/j.addr.2022.114394 ↗
53. 10.1016/j.cej.2020.12729610.1016/j.cej.2020.127296 ↗
54. 10.1016/j.jconrel.2022.06.05310.1016/j.jconrel.2022.06.053 ↗
55. 10.1016/j.jconrel.2023.02.03610.1016/j.jconrel.2023.02.036 ↗
56. 10.1038/s41569-020-0429-110.1038/s41569-020-0429-1 ↗
57. 10.1038/s41467-020-16439-710.1038/s41467-020-16439-7 ↗
58. 10.1016/j.cej.2022.13899210.1016/j.cej.2022.138992 ↗
59. 10.1038/s41467-019-08670-810.1038/s41467-019-08670-8 ↗
60. 10.1002/anie.20210430410.1002/anie.202104304 ↗
61. 10.1016/j.jacbts.2023.07.01710.1016/j.jacbts.2023.07.017 ↗
62. 10.1016/j.colsurfb.2017.05.05610.1016/j.colsurfb.2017.05.056 ↗
63. 10.1016/j.progpolymsci.2016.01.00210.1016/j.progpolymsci.2016.01.002 ↗
64. 10.1016/j.cell.2022.04.00410.1016/j.cell.2022.04.004 ↗
65. 10.1016/j.phrs.2021.10581910.1016/j.phrs.2021.105819 ↗
66. 10.1080/20013078.2019.162665410.1080/20013078.2019.1626654 ↗
67. 10.1073/pnas.75.7.332710.1073/pnas.75.7.3327 ↗
68. 10.1016/j.atherosclerosis.2016.01.04410.1016/j.atherosclerosis.2016.01.044 ↗
69. Liu B. · Mol. Cell Biomech. · 2010 · 7 · 193
70. 10.1016/j.yjmcc.2018.08.02610.1016/j.yjmcc.2018.08.026 ↗
71. 10.1016/j.biomaterials.2021.12067710.1016/j.biomaterials.2021.120677 ↗
72. 10.1016/j.ejphar.2020.17340810.1016/j.ejphar.2020.173408 ↗
73. 10.1016/j.msec.2021.11216410.1016/j.msec.2021.112164 ↗
74. 10.1039/D1NR05355H10.1039/D1NR05355H ↗
75. 10.3390/pharmaceutics1206055510.3390/pharmaceutics12060555 ↗
76. 10.1093/rb/rbab03310.1093/rb/rbab033 ↗
77. 10.1021/acsami.1c0855210.1021/acsami.1c08552 ↗
78. 10.1186/s12951-020-00744-w10.1186/s12951-020-00744-w ↗
79. 10.1002/adfm.20200213110.1002/adfm.202002131 ↗
80. 10.1016/j.biomaterials.2017.07.03510.1016/j.biomaterials.2017.07.035 ↗
81. 10.1016/j.atherosclerosis.2019.08.01210.1016/j.atherosclerosis.2019.08.012 ↗
82. 10.1039/C9RA05176G10.1039/C9RA05176G ↗
83. 10.2147/IJN.S12425210.2147/IJN.S124252 ↗
84. 10.1093/cvr/cvz02710.1093/cvr/cvz027 ↗
85. 10.1016/j.cclet.2021.10.05510.1016/j.cclet.2021.10.055 ↗
86. 10.1161/01.ATV.0000229218.97976.4310.1161/01.ATV.0000229218.97976.43 ↗
87. 10.1016/j.biomaterials.2022.12173410.1016/j.biomaterials.2022.121734 ↗
88. 10.1016/j.cej.2021.12974410.1016/j.cej.2021.129744 ↗
89. 10.1016/j.jddst.2020.10151010.1016/j.jddst.2020.101510 ↗
90. 10.1039/C8BM00389K10.1039/C8BM00389K ↗
91. 10.1016/j.matlet.2019.12725410.1016/j.matlet.2019.127254 ↗
92. 10.1016/j.jconrel.2021.11.02710.1016/j.jconrel.2021.11.027 ↗
93. 10.1021/acsami.2c0235410.1021/acsami.2c02354 ↗
94. 10.1016/j.bioactmat.2022.03.04110.1016/j.bioactmat.2022.03.041 ↗
95. 10.1016/S0021-9150(96)06035-210.1016/S0021-9150(96)06035-2 ↗
96. 10.1016/j.cej.2023.14679210.1016/j.cej.2023.146792 ↗
97. 10.1016/j.ejphar.2017.09.00710.1016/j.ejphar.2017.09.007 ↗
98. Brown B. A. · 2017 · 147 · 197
99. 10.3892/etm.2017.566010.3892/etm.2017.5660 ↗
100. 10.1016/j.jss.2019.06.10210.1016/j.jss.2019.06.102 ↗